Contract awardedGenomic sequencing platforms and consumables

Adaptive Biotechnologies supplies the Royal Marsden's clonoSEQ MRD assay

The Royal Marsden NHS Foundation Trust buys the clonoSEQ assay from Adaptive Biotechnologies Corporation to track minimal residual disease (MRD) in blood cancer patients. The next-generation sequencing test covers conditions such as chronic lymphocytic leukaemia, acute lymphoblastic leukaemia and multiple myeloma.

The trust required a test that works on DNA, reaches an MRD sensitivity of 10⁻⁵ or lower and can track clonal evolution. Alongside the kits and reagents, Adaptive provides training and support for laboratory and clinical staff, plus a software platform to analyse and report results.

The trust awarded the £1,158,208 contract directly. It runs for five years, from January 2026 to January 2031.

Alert me to similar tenders

Contract ends January 2031

What
Genomic sequencing platforms and consumables
Value
£1.16m
How it was bought
Direct
Dates and next
Jan 2026 to Jan 2031

How it was bought

2 official notices
  1. 22 Dec 2025Award noticeFind a Tender
  2. 30 Dec 2025Award noticeFind a Tender
  3. 20 Jan 2026Contract starts
  4. 19 Jan 2031Contract ends

The Royal Marsden NHS Foundation Trust has bought this 4 times since 2021

Last bought
Dec 2025
Typical length
2 years
Typical value
£966,619
Suppliers used
3
AwardedContractWon byValue
Dec 2025This purchase5 yearsAdaptive Biotechnologies Corporation£1.16m
Aug 2025Locked1 yearLocked£775,030
Jul 2025Locked2 yearsLocked£674,440
Oct 2021LockedLocked£1.64m

Suppliers The Royal Marsden NHS Foundation Trust has used

SupplierContractsValue
Adaptive Biotechnologies Corporation Won this one1£1.16m
Locked1£775,030
Locked1£674,440
See the contracts and who won them

Figures to 21 November 2026

How it compares

With every genomic sequencing platforms and consumables award since 2021

Half of awards fall between £39,025 and £264,721Median £85,266

Awards
383
Firms that won them
60
Median award
£85,266
of 375 with a value
This award
Bigger than 92%
of them
Typical length
1 year
In London
87 awards

Adaptive Biotechnologies Corporation ranks 26th of 60 firms for genomic sequencing platforms and consumables awards since 2021.

RankFirmAwardsValue
1Locked133£67.5m
2Locked55£22.9m
3Locked38£4.88m
4Locked30£11.6m
5Locked11£2.87m
6Locked9£484,451
26Adaptive Biotechnologies Corporation Won this one1£1.16m
See who wins this work

Genomic sequencing platforms and consumables at other buyers

The Royal Marsden NHS Foundation Trust has awarded 55 contracts since 2021.

See The Royal Marsden NHS Foundation Trust's page
  • Adaptive Biotechnologies Corporation has won 1 public contract since 2021.